ECSP17022542A - Inhibidores de la histona desmetilasa - Google Patents

Inhibidores de la histona desmetilasa

Info

Publication number
ECSP17022542A
ECSP17022542A ECIEPI201722542A ECPI201722542A ECSP17022542A EC SP17022542 A ECSP17022542 A EC SP17022542A EC IEPI201722542 A ECIEPI201722542 A EC IEPI201722542A EC PI201722542 A ECPI201722542 A EC PI201722542A EC SP17022542 A ECSP17022542 A EC SP17022542A
Authority
EC
Ecuador
Prior art keywords
cancer
compositions
compounds
histone
desmetilase
Prior art date
Application number
ECIEPI201722542A
Other languages
English (en)
Inventor
Michael Brennan Wallace
Young K Chen
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of ECSP17022542A publication Critical patent/ECSP17022542A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere en general a composiciones y métodos para tratar el cáncer y enfermedad neoplásica. En este documento se proporcionan compuestos derivados de pirrolopiridina sustituidos y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones objeto son útiles para la inhibición de la histona desmetilasa. Además, los compuestos y composiciones objeto son útiles para el tratamiento de cáncer, tal como cáncer de próstata, cáncer de mama, cáncer de vejiga, cáncer de pulmón y/o melanoma y similares.
ECIEPI201722542A 2014-09-17 2017-04-11 Inhibidores de la histona desmetilasa ECSP17022542A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051850P 2014-09-17 2014-09-17

Publications (1)

Publication Number Publication Date
ECSP17022542A true ECSP17022542A (es) 2017-05-31

Family

ID=55533717

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201722542A ECSP17022542A (es) 2014-09-17 2017-04-11 Inhibidores de la histona desmetilasa

Country Status (17)

Country Link
US (3) US9758517B2 (es)
EP (1) EP3194387B1 (es)
JP (2) JP6723663B2 (es)
KR (1) KR20170048601A (es)
CN (1) CN107001330A (es)
AU (1) AU2015318111A1 (es)
BR (1) BR112017005510A2 (es)
CA (1) CA2961580A1 (es)
CL (1) CL2017000662A1 (es)
CO (1) CO2017003445A2 (es)
EA (1) EA201790604A1 (es)
EC (1) ECSP17022542A (es)
ES (1) ES2751464T3 (es)
IL (1) IL251184A0 (es)
MX (1) MX2017003463A (es)
SG (1) SG11201702119PA (es)
WO (1) WO2016044138A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738637B2 (en) 2013-03-12 2017-08-22 Celgene Quantical Research, Inc. Histone demethylase inhibitors
EA201790604A1 (ru) * 2014-09-17 2017-09-29 Селджен Квонтисел Рисёрч, Инк. Ингибиторы гистондеметилазы
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP7090639B2 (ja) * 2017-04-11 2022-06-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド フッ素置換されたインダゾール化合物及びその使用
CN109709333B (zh) * 2018-08-01 2021-09-24 东南大学 H4k20、h3k9及h3k36三甲基化量检测试剂在食管癌预后评估中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2008070011A2 (en) 2006-12-04 2008-06-12 Novartis Ag Combination of an hdac inhibitor and an antimetabolite
US20100137398A1 (en) 2007-05-04 2010-06-03 Novartis Ag Use of hdac inhibitors for the treatment of gastrointestinal cancers
PT2499139E (pt) * 2009-11-10 2014-02-10 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
WO2013028999A1 (en) 2011-08-24 2013-02-28 The Trustees Of Columbia University In The City Of New York Small molecule inducers of gdnf as potential new therapeutics for neuropsychiatric disorders
BR112015007083A2 (pt) * 2012-10-02 2017-07-04 Epitherapeutics Aps inibidores de histona demetilases
HUE037312T2 (hu) 2012-12-19 2018-08-28 Celgene Quanticel Res Inc Hiszton demetiláz inhibitorok
US9738637B2 (en) * 2013-03-12 2017-08-22 Celgene Quantical Research, Inc. Histone demethylase inhibitors
EA201790604A1 (ru) * 2014-09-17 2017-09-29 Селджен Квонтисел Рисёрч, Инк. Ингибиторы гистондеметилазы

Also Published As

Publication number Publication date
US20160108032A1 (en) 2016-04-21
JP6723663B2 (ja) 2020-07-15
EA201790604A1 (ru) 2017-09-29
US10231957B2 (en) 2019-03-19
ES2751464T3 (es) 2020-03-31
EP3194387B1 (en) 2019-07-31
CL2017000662A1 (es) 2018-03-23
WO2016044138A1 (en) 2016-03-24
IL251184A0 (en) 2017-05-29
CN107001330A (zh) 2017-08-01
US9758517B2 (en) 2017-09-12
US20170326116A1 (en) 2017-11-16
US10016401B2 (en) 2018-07-10
EP3194387A4 (en) 2018-03-07
CO2017003445A2 (es) 2017-07-11
BR112017005510A2 (pt) 2018-08-14
SG11201702119PA (en) 2017-04-27
KR20170048601A (ko) 2017-05-08
AU2015318111A1 (en) 2017-04-13
CA2961580A1 (en) 2016-03-24
MX2017003463A (es) 2017-07-13
JP2020169183A (ja) 2020-10-15
US20180271843A1 (en) 2018-09-27
EP3194387A1 (en) 2017-07-26
JP2017529347A (ja) 2017-10-05
JP6967632B2 (ja) 2021-11-17

Similar Documents

Publication Publication Date Title
CO2017002191A2 (es) Inhibidores de desmetilasa-1 específica a lisina
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
ECSP15030527A (es) Inhibidores de histona desmetilasa
ECSP17006821A (es) Inhibidores de la desmetilasa-1 específica de la lisina
ECSP17006776A (es) Inhibidores de la desmetilasa-1 específica de la lisina
CO2017000359A2 (es) Compuestos derivados de piridina sustituidos como inhibidores de histonas desmetilasa
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
MX2016007585A (es) Inhibidores de desmetilasa-1 especifica de lisina.
ECSP17023551A (es) Inhibidores de histona desmetilasa
ECSP17020172A (es) Inhibidores de histona desmetilasa
CO2017003445A2 (es) Inhibidores de la histona desmetilasa